1. Home
  2. HALO vs TECH Comparison

HALO vs TECH Comparison

Compare HALO & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Halozyme Therapeutics Inc.

HALO

Halozyme Therapeutics Inc.

HOLD

Current Price

$78.05

Market Cap

8.1B

Sector

Health Care

ML Signal

HOLD

Logo Bio-Techne Corp

TECH

Bio-Techne Corp

HOLD

Current Price

$71.77

Market Cap

9.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HALO
TECH
Founded
1998
1976
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.1B
9.1B
IPO Year
2001
1995

Fundamental Metrics

Financial Performance
Metric
HALO
TECH
Price
$78.05
$71.77
Analyst Decision
Buy
Strong Buy
Analyst Count
11
11
Target Price
$78.64
$71.82
AVG Volume (30 Days)
1.8M
7.6M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
0.62%
EPS Growth
N/A
N/A
EPS
1.22
0.81
Revenue
$151,862,000.00
$1,219,635,000.00
Revenue This Year
$28.24
$2.49
Revenue Next Year
$12.56
$6.40
P/E Ratio
$63.51
$88.62
Revenue Growth
N/A
5.23
52 Week Low
$55.64
$43.20
52 Week High
$82.26
$72.16

Technical Indicators

Market Signals
Indicator
HALO
TECH
Relative Strength Index (RSI) 59.28 77.15
Support Level $67.12 $70.49
Resistance Level $82.24 $72.16
Average True Range (ATR) 2.46 0.39
MACD -0.33 -0.35
Stochastic Oscillator 46.95 87.44

Price Performance

Historical Comparison
HALO
TECH

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

About TECH Bio-Techne Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Share on Social Networks: